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Abstract
Background: Substantial recent research examines the efficacy of many types of complementary and alternative (CAM)
therapies. However, outcomes associated with the “real-world” use of CAM has been largely overlooked, despite calls for
CAM therapies to be studied in the manner in which they are practiced. Americans seek CAM treatments far more
often for chronic musculoskeletal pain (CMP) than for any other condition. Among CAM treatments for CMP,
acupuncture and chiropractic (A/C) care are among those with the highest acceptance by physician groups and the
best evidence to support their use. Further, recent alarming increases in delivery of opioid treatment and surgical
interventions for chronic pain–despite their high costs, potential adverse effects, and modest efficacy–suggests the
need to evaluate real world outcomes associated with promising non-pharmacological/non-surgical CAM treatments
for CMP, which are often well accepted by patients and increasingly used in the community.
Methods/Design: This multi-phase, mixed methods study will: (1) conduct a retrospective study using information
from electronic medical records (EMRs) of a large HMO to identify unique clusters of patients with CMP (e.g., those
with differing demographics, histories of pain condition, use of allopathic and CAM health services, and
comorbidity profiles) that may be associated with different propensities for A/C utilization and/or differential
outcomes associated with such care; (2) use qualitative interviews to explore allopathic providers’
recommendations for A/C and patients’ decisions to pursue and retain CAM care; and (3) prospectively evaluate
health services/costs and broader clinical and functional outcomes associated with the receipt of A/C relative to
carefully matched comparison participants receiving traditional CMP services. Sensitivity analyses will compare
methods relying solely on EMR-derived data versus analyses supplementing EMR data with conventionally
collected patient and clinician data.
Discussion: Successful completion of these aggregate aims will provide an evaluation of outcomes associated with
the real-world use of A/C services. The trio of retrospective, qualitative, and prospective study will also provide a
clearer understanding of the decision-making processes behind the use of A/C for CMP and a transportable
methodology that can be applied to other health care settings, CAM treatments, and clinical populations.
Trial registration: ClinicalTrials.gov: NCT01345409
Background
We describe here our study designed to understand
clinically meaningful outcomes (from both patient and
provider perspectives) of acupuncture and chiropractic
(A/C) care as delivered in routine practice settings for
the treatment of chronic musculoskeletal pain (CMP).
The centerpiece of the study is a prospective cohort
study. However, before we undertake this phase of
work, we will conduct an analysis of electronic medical
record (EMR) data and qualitative data collection to
provide the foundation for identifying a more meaning-
ful comparison of outcomes between those receiving
and not receiving A/C care. Our goal is to test an
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understand critical outcomes associated with the receipt
of an array of treatment services in everyday practice
settings for a realistically diverse set of patients.
Chronic pain is a highly prevalent condition, often
resulting in large decrements in health-related quality of
life (QOL) and functional status, with substantial asso-
ciated medical care costs, disability, and productivity
loss [1-3]. CMP in particular is both prevalent and
costly [4-7], affecting 60-80% of American adults at
some point during their lives; CMP symptoms are
among the top five reasons that patients visit clinics and
emergency departments [6,8]. Recent alarming increases
in delivery of opioid treatment and surgical interven-
tions for chronic pain–despite their high costs, potential
adverse effects, and modest efficacy [9-12]–suggest the
need to evaluate outcomes associated with promising
non-pharmacological/non-surgical approaches for CMP
management and treatment, including complementary
and alterative medicine (CAM). Americans seek CAM
treatments far more often for CMP than for any other
condition [13].
Substantial recent research has examined the biologi-
cal basis and efficacy of many types of CAM therapies
but, despite calls for effectiveness-oriented research,
“real-world” use of CAM remains understudied [14,15].
Use of CAM for CMP appears to be increasing. A
national survey [13] found that 38% of U.S. adults used
some form of CAM, most commonly for relief of back
and neck pain, joint pain and stiffness, arthritis, and
other musculoskeletal conditions. Among CAM treat-
ments for CMP, acupuncture and chiropractic care are
considered the most highly accepted by physician
groups [16,17] with the best evidence to support their
use [18-21]. Nearly 90% of states mandate insurance
reimbursement for chiropractic care and approximately
25% do so for acupuncture [22]. Further, a survey of
acupuncturists and chiropractors in Massachusetts, Ari-
zona, and Washington found that back pain was the
most common reason given by patients for seeking
treatments; overall, 40-76% of patients included CMP
among their reasons for seeking such treatment [23].
Patients also report high levels of satisfaction with
acupuncture [24] and chiropractic care [18]. A Consu-
mer Reports survey found that while more than half of
the respondents reported being highly satisfied with care
from acupuncturists (53%) and chiropractors (59%) for
back pain, only 44% reported similar satisfaction with
care from specialist physicians and 34% with care from
primary care physicians [25]. Despite some positive find-
ings among observational studies and randomized con-
trolled trials (RCTs) regarding the impact of
acupuncture [18,26,27] and chiropractic care [18,28-30]
on CMP, highly controlled trials have suggested that
expectation and non-specific effects may be substantial
contributors to observed treatment effects [31-33].
These findings highlight the importance of examining
patient expectations and treatment decision-making fac-
tors when evaluating such outcomes. Given both the
popularity of A/C for CMP treatment and outcome
findings, an important next step is to examine the use
of these CAM therapies for CMP as they are delivered
by providers in routine practice settings.
Multiple recent reports [14,15,34,35] suggest the
importance for health services research to explore mod-
els of organized health delivery that integrate CAM with
conventional medicine. Until recently, patients were
likely to make decisions about whether to use CAM ser-
vices without input from allopathic providers [36,37],
but today’sp a t i e n t sa r ei n c r e a s i n g l y“co-managed” by
conventional and CAM clinicians. Most patients report
using CAM and conventional medicine together and
want the opportunity to discuss CAM use with their pri-
mary care providers, be respected for their beliefs, and
be guided on their use of such treatments [38-40]. Many
CAM therapies are used to complement, rather than
replace, conventional medicine; therefore, it is important
to identify a model that can serve as a unified frame-
work for the decision to use A/C within this context.
Thus, we chose a framework to guide our exploration of
patients’ decisions to use A/C based on a well-accepted
model for general health care decision-making and use
[41,42], that has been expanded to consider integration
of CAM services (see Figure 1)[43]. This model for
CAM use includes commonly used self-directed prac-
tices and products as well as provider services that are
the central focus of this study. Further, the model
includes indicators that may “pull” a person toward A/C
use (e.g., responsibility for preventive self-care) or
“push” patients (e.g., dissatisfaction with conventional
medicine)[44,45]. Research on conventional medicine
use suggests that enabling factors (e.g., access, informa-
tion about forms of care) and need (e.g., type and level
of impairment) are the primary drivers of health care
decisions [46-48], but their relative importance has not
been explored for A/C service use.
This project will use data collected from a prepaid
group practice model health maintenance organization
(HMO) that offers A/C coverage for CMP treatment; in
this setting, enabling factors of access (insurance cover-
age, co-pays, lower out-of-pocket costs) will likely miti-
gate the influence of economic factors [47,49,50].
Consequently, we will be able to explore more fully those
non-financial predisposing and need factors that affect
A/C decision making. This framework also helps guide
us toward the most important domains for measurement.
Finally, there is increased demand for innovative study
designs using data from routi n ep r a c t i c es e t t i n g st o
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interventions. Ideal settings are health care systems that
use EMRs, provide insurance coverage, and document
the use of provider-delivered CAM services, such as A/
C care. Innovative research designs in these settings can
provide information for health care providers and
patients about which CAM and conventional treatments
a r el i k e l yt op r o v i d et h eb e s t clinical, functional, and
quality-of-life outcomes for everyday users in routine
practice settings [51-53]. These designs will include a
more diverse range of study subjects than would RCTs
and allow longer follow-up, facilitating identification of
groups that may uniquely benefit or encounter compli-
cations. These settings permit study designs that can
examine the full array of treatments and associated out-
comes that patients may encounter.
Despite these advantages, making causal inferences in
observational studies is more challenging than in RCTs
because of confounding by indication. That is, patients
(and/or doctors) choose treatments using information
that may not be evident to researchers. Patients who
receive a given treatment in everyday practice may be
dissimilar from their counterparts who do not, in which
case treatment outcomes may be at least partially related
to unmeasured pre-treatment differences rather than the
treatment received. For pre-treatment differences where
we have valid information, recent analytic techniques
offer the promise of identifying patients with similar
probability of receiving a particular treatment [54-58].
In the event that one of these patients receives the treat-
ment and the other does not, clinical outcomes may be
validly compared for such individuals. Using such
approaches can complement what can be achieved with
RCTs relatively quickly and efficiently. Such observa-
tional studies can highlight important domains for sub-
sequent confirmatory RCTs or point to patterns of
utilization and outcomes that are not predicted by exist-
ing RCTs.
The aims of the present study are two-fold. The first
goal is to examine who (i.e., CMP patients with what
characteristics and history of clinical care) will have
improved outcomes from A/C care, and to identify the
specific characteristics of such care (e.g., duration, com-
prehensiveness of employed A/C modalities). The sec-
ond goal is to test an exportable methodological
approach that can be used to examine clinically mean-
ingful outcomes for patients: (1) in different settings, (2)
using different types of CAM or conventional medical
Figure 1 Patient Factors Influencing the Decision to Use Acupuncture and/or Chiropractic Care (A/C) for Chronic Musculoskeletal Pain.
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characteristics.
Methods/Design
Study Overview
The overarching goal of this multi-phase, mixed meth-
ods study is to understand the real world implications
for patient care and patient satisfaction of acupuncture
and/or chiropractic treatment for CMP. Our study set-
ting is a closed patient population HMO in which
insurance coverage has been available for A/C treat-
ments. In order to accomplish our goal, we divided our
work into three complementary but distinct phases as
summarized in Figure 2. Phase 1 involves assembling
and exploring a research database with 5 years (2006-
2010) of prospectively collected elements available
within the HMO. We will identify HMO members who
satisfy our study definition of CMP (see Table 1). The
database will include members with evidence of using
A/C services and a matched comparison group without
such evidence. We will then compare these groups on
clinical care outcomes andc o s t sd e r i v e du s i n gE M R
data. These analyses will be augmented with patient-
reported out-of-plan A/C utilization. Phase 2 includes
qualitative methods to describe the characteristics of A/
C services received by HMO-based CMP patients and
the decision-making processes of allopathic providers
and patients in choosing such services; this will allow us
to design the appropriate data collection tools and stra-
tegies for Phase 3. During Phase 3, we will conduct a
longitudinal prospective cohort study of carefully
matched samples of A/C and non-A/C patients. Partici-
pant selection will rely upon clustering/matching meth-
ods identified during Phase 1, refined by Phase 2
qualitative findings, and augmented by additional,
direct-assessed patient-report baseline data. Outcomes
will include EMR-derived utilization information and
patient-reported outcomes. The patient-reported out-
comes will cover clinical, psychosocial, quality of life,
service utilization, and health care costs over 12
months. We will develop and/or refine these outcomes
in the process of Phase 1 data exploration and Phase 2
qualitative research that explores outcomes that are
clinically meaningful to conventional and CAM provi-
ders and are associated with high levels of patient satis-
faction. Finally, we will compare outcomes from this
augmented data set to those found during the Phase 1
EMR-only analyses, conducting sensitivity analyses to
test the robustness of our findings and transportability
of methodology. While phases 1 and 2 can stand alone,
in this project they are preparatory to Phase 3, the long-
itudinal prospective cohort study.
Figure 2 Study Phases, Procedures, and Chronic Musculoskeletal Pain (CMP) Participant Flow.
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This study is being conducted at Kaiser Permanente
Northwest (KPNW), a large HMO in the Pacific
Northwest with several features that create a uniquely
favorable environment for this research. First, KPNW
has an extensive history of CAM integration. Due to
Washington State’s 1998 law [59] mandating insurance
coverage for a broad array of licensed providers
(including chiropractors and acupuncturists), KPNW
began to offer CAM coverage for all health plan mem-
bers. Administration of thisc o v e r a g ei sp r o v i d e db ya
managed complementary care network that maintains
electronic data from HCFA-1500 forms (including
information on diagnoses, procedures, and dates of
service) and these data are available to the project.
Second, any health plan member can be referred by a
KPNW clinician for A/C care for qualifying conditions,
including acupuncture for CMP and chiropractic care
for acute exacerbations of CMP conditions. Although
some patients pay out-of-pocket for A/C care, our out-
of-plan CAM use survey will help us discern this pre-
valence. Third, in 1995, KPNW implemented a com-
prehensive EMR system (HealthConnect) that has
since captured A/C services and documented all outpa-
tient provider encounters, diagnoses, referrals, labora-
tory and imaging studies, and prescriptions. The HMO
provides most services in its own hospitals and clinics,
yet data are compiled and available on reimbursable
external services received by health plan patients.
Together these provide an all-inclusive picture of
members’ covered health care utilization.
Study participants
Study participants are health plan members aged 18 or
older with evidence of CMP. To identify such patients
from the EMR, we use ICD-9 codes consistent with
CMP-related diagnoses, as outlined in Table 1. Muscu-
loskeletal pain is thought to contribute to tension head-
aches, carpal tunnel syndrome, and temporomandibular
disorders (TMD). Accordingly, and because A/C care is
sometimes sought for the treatment of such conditions,
we include participants with these diagnoses. To ensure
chronicity of the pain disorder, visits must indicate such
diagnoses or receipt of commensurate health services
spanning at least 180 days. Exclusion criteria include
history of cancer or cancer-related pain, hospice or
other end-of-life palliative care, cognitive impairment
(dementia, developmental delay, and psychosis) that
would make it unlikely that the patient would receive
A/C and/or could participate in study assessments. In
later sections, we describe additional inclusion and
exclusion criteria specific to the qualitative (Phase 2)
and prospective cohort (Phase 3) portions of the study.
Preliminary analyses indicate that during a recent
calendar year (2010), almost 24% (N = 71,584) of our
304, 034 current health plan members ≥ 18 years of age
met criteria for current or recent CMP;, a high preva-
lence in the study setting even when using a stringent
definition of chronic pain (at least six months’ duration
of symptoms). Further, 36% of these CMP patients met
criteria for more than one type of chronic pain (see
Table 2), suggesting the importance of including partici-
pants with more complex conditions (i.e., multiple
Table 1 Overall Study Eligibility Criteria
Inclusion criteria:
≥ 18 years of age
Meets the following definition of musculoskeletal pain as determined review of the individual’s electronic medical record (EMR) chart:
≥ 3 outpatient (emergency department, ambulatory visit, email and telephone encounters are acceptable) encounters spanning at least 180
days but no more than 18 months:
nonspecific chronic pain (nCP)
or chronic musculoskeletal pain (CMP). CMP includes arthritis, temporomandibular joint disorder, tension headaches, carpal tunnel
syndrome, fibromyalgia and myofascial pain, pain in limb, pain in joint, back/neck pain, vertebral fractures, vertebral somatic dysfunction,
spondylolysis, vertebral dislocation, spinal strains and sprains, spinal deformities
Three qualifying diagnoses can be achieved in any of the following ways:
Three CMP diagnoses
First diagnosis CMP and two subsequent diagnoses of nCP
First diagnosis CMP with one additional CMP diagnosis and one nCP
Diagnoses associated with a physical therapy visit will NOT be considered in identifying prospective participants
Only one CMP/nCP diagnosis can be counted in any given 7-day window to minimize the possibility that qualifying diagnoses reflect multiple
visits/services for the same acute pain condition.
Study participant exclusion criteria include:
Medical history of malignant cancer other than non-melanoma skin cancer
Medical history of cognitive impairment (dementia, developmental delay, or psychosis)
Medical history of hospice or end-of-life palliative care
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examine care in routine settings.
Phase 1: Construction of CMP sample and A/C Services
Using EMR Data and an Out-of-Plan CAM Use Survey
The first phase of the project involves constructing a
sample of HMO members with CMP over a five-year
period (1/01/2006-12/31/2010). One difference between
EMR-based and RCT-based research is the importance
of the occurrence of medical events over time, in the
absence of any research intervention. Each patient in the
sample will have a virtual enrollment date, at which they
first satisfied the CMP-eligibility criteria. All EMR data
prior to that date correspond roughly to “baseline” data
in an RCT, the primary difference being that the
amount and duration of EMR-based events will almost
certainly vary widely from patient to patient. As one
moves forward from the virtual enrollment date, a given
patient can be considered to be someone who uses A/C
during that time period if they initiate A/C visits, or not
if they rely solely on conventional care. Consequently,
whether a patient is considered as treated (with A/C) or
“control” (without A/C) depends on the time period
over which outcome events are accumulated. This fea-
ture substantially complicates the analysis, above and
beyond the absence of a formal intervention. Those who
receive A/C treatment or are identified as “control” sub-
jects can then be compared on clinical care outcomes
and costs derived from EMR data.
Phase 1 includes a focus on analytic innovations that
capitalize on our very large data set (122, 896 health
plan members with EMR-identified CMP from 2006 to
2010) to describe pain-related services. We will also
explore and compare outcomes found through multiple
methods for identifying suitable comparable groups of
patients (those who did and did not receive A/C ser-
vices) and best controlling for potential confounders
between the groups. This approach is consistent with
recommendations for observational studies to employ
multiple analytic strategies to ensure consistency of
findings [60]. Reviewed below are our methods for orga-
nizing our data and creating descriptions of trajectories
of pain care services (event-stream methods) followed
by the three principal analytic approaches to be
employed to match participants receiving A/C to suita-
ble controls - selection models, propensity score analy-
sis, and the analysis of matched comparison groups.
These analytic methods will be oriented toward reduc-
tion of indication bias.
Event-stream methods
Management of longitudinal patient records is difficult
because patients receive services in diverse ways.
Unlike clinical trials in which all measures are col-
lected in the same time frame, clinical records include
patients who visit the health plan at different times for
different services, each displaying a unique, idiographic
“trajectory of care.” For CMP patients, for example,
this might include use of patient education, physical
therapy, and opiate medications over a particular per-
iod of time. The event-stream method allows a richer
description of patient care over time, more consistent
with how patients receive services in routine care. The
Table 2 KPNW Health Plan Members with CMP in 2010
No CAM referral in 2010 Chiropractic and/or acupuncture referral in 2010*
Mean (SD) or % (N) Mean (SD) or % (N)
Total members 18 and older with CMP 66768 4816
Type of Chronic Pain
Back and Neck Pain 33248 4244
Joint Pain (including Osteoarthritis) 40308 2705
Fibromyalgia and other Myofascial Pain 7129 1125
Headache 7543 743
Two or more types of pain from CMP definition 34.3% (22904) 61.9% (2983)
Two or more types of pain from more general
chronic pain definition
38.1% (25419) 63.4% (3052)
Demographics
% female 61.4% (41058) 68.3% (3290)
Age 57.4 (15.5) 52.3 (14.8)
% White (1) 87.6% (54982) 87.4% (3996)
% Hispanic (2) 6.3% (2379) 6.8% (206)
Other
Depression diagnosis 20.6% (13780) 26.8% (1292)
Sleep problems 0.46% (307) 0.89% (43)
*2224 chiropractic only, 2314 acupuncture only, 278 both.
(1) race information only available for 67, 319 health plan members, (2) ethnicity for 41, 098 health plan members
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clinical/administrative databases and the analysis data-
sets [61,62]. Event-stream methods can be used to
construct the types of variables that can then be used
in a conventional analysis. This approach simplifies
both the data extraction and statistical analysis and
allows a richer array of variables for identifying
matches or clusters of patients.
Selection models
To compare CMP patients who are users and non-users
of A/C care on their health care utilization, we will need
to adjust for features that might be associated with both
the use of CAM (A/C care) and health care utilization
overall. One of the challenges the project will address
will be to determine the potential confounding factors
from the EMR data alone. The chief threat to the valid-
ity of clinical observational studies is indication bias, in
which factors that predict clinical outcomes are asso-
ciated with treatment choices. This problem is not
unique to biomedical research, and in fact the founda-
tional development of selection models was carried out
in economics [63]. Therefore, Heckman’s selection mod-
els will be used to produce analyses based on joint esti-
mation in a regression model (for the outcome) and a
logistic regression model (for the treatment selection),
which permits these two processes to be linked. Of all
the approaches to be used in this project, this is the one
that most closely mirrors statistical analysis in a conven-
tional clinical trial.
Propensity score analysis
Another method we will use to model the probability of
being referred for and obtaining CAM treatment is pro-
pensity score analysis [56,59,64-66]. Propensity scoring
is an increasingly accepted collection of techniques to
adjust for non-random selection among groups within
observational studies. This approach is designed to
remove most of the imbalance associated with the mea-
sured characteristics of cases allowing less biased esti-
mates of treatment effect and other quantities linked
with treatment (e.g., cost, quality of life). Propensity
scores are designed to extract all of the relevant infor-
mation from potential confounding variables. A conse-
quence of this method is that two people in the same
propensity stratum would be equally likely to receive the
(CAM) treatment, after conditioning on all their known
pre-treatment characteristics, which justifies an entirely
conventional analysis. We will follow the modern litera-
ture on propensity scoring to use multiple models with
different forms and assumptions, as this is the only way
known to probe the validity of the resulting analyses.
Table 3 includes a list of EMR variables available to us
for this purpose.
Analysis of Matched Comparison Groups (MCG)
The third and primary approach we anticipate using to
matching participants receiving A/C to suitable controls
is the analysis of matched comparison groups. This
approach is based on the notion that if, at a particular
time, one can form a group of patients who are well-
matched on prognostic factors, then within such a
group decisions whether to use A/C cannot be based on
the matching factors and must be weakly associated
with unmeasured factors that are correlated with mea-
sured matching factors, thus tending to remove indica-
tion bias. If this type of matching were perfectly
successful, then the absence of formal randomization
would become irrelevant. In the analysis, one would
compute treatment effects at the MCG level. Subsequent
analysis would search for consistent results across simi-
lar MCGs, and in the presence of such similarity, accu-
mulation of results would be applied to patient
subpopulations. Formation of MCGs will be aided by
the affinity clustering technique [54,67], which can be
employed in large samples and has the advantage of
identifying an “exemplar” patient whose variables repre-
sent those of the MCG members, thus making it possi-
ble to characterize MCGs at the analysis stage. Variables
from the EMR include the patient characteristics and
care variables delineated in Table 3. Available variables
include many of those posited to be important factors in
patients’ decisions to use CAM therapies, as delineated
in Figure 1 (Boxes A-C). Our large study patient pool
study makes it possible to find MCGs of relatively clo-
sely matched CMP patients. We anticipate finding a
large number of MCGs, each small and highly homoge-
neous. Outcomes will consist of various utilization mea-
sures, both generally and specific to CMP (see Table 4).
We do not anticipate statistical significance at the MCG
level due to their small size; rather, we intend to aggre-
gate results across MCGs to investigate homogeneity of
Table 3 Phase 1: Variables available from EMR for
Clustering/Matching Patients
Types/duration of pain condition(s)
Pain severity
Comorbid conditions (e.g., depression, obesity)
Demographics (age, gender, race, marital status, employment status)
Receipt of pain-related disability compensation
Overall healthcare service use
Prescription medications received (e.g., short and long-acting opiates,
sedatives, hypnotics, and antidepressants)
Pain-related procedures received (injections, imaging, and surgeries)
Pain-related visits (primary and specialty care including physical therapy)
ER/urgent care visits
Prior use of health insurance reimbursed CAM
Characteristics of primary care provider (e.g., degree [MD, DO, NP]
frequency of CAM referrals, gender)
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to MCG exemplar characteristics.
Outcome analyses
In identifying MCGs, we will use all CMP patient EMR
data collected over a 5-year span (2006-2010). Patients
must have a long enough duration of consecutive health
plan membership to establish CMP eligibility and evalu-
ate outcomes over the following year. To ensure maxi-
mum comparability, eligible patients must have clinical
data available over a period when the A/C referral pat-
terns were highly comparable. For each analytic
approach, for each outcome measure, an A/C effect
(comparing A/C and non-A/C patients) will be com-
puted for each informative MCG. Table 4 shows the
EMR-derived clinical outcomes that we plan to examine.
We will employ conventional between-group estimates
of the A/C effect measures. We anticipate, however, that
there may be substantial heterogeneity of A/C effects
across MCGs, so that it will be important to character-
ize where A/C has a beneficial effect, no effect, or an
adverse effect. We will use both graphical methods as
well as clustering of MCGs. We will also use explana-
tory linear models, usually ordinary regression, but
potentially variants, depending on the specific type of
outcome.
Multiple levels of analysis
In clinical trials, it is appropriate to pre-specify the main
analyses; however, in clinical non-intervention research,
the reverse is the case. As emphasized in Guo and Fra-
ser [60], because each analytic approach has its own
strengths and weaknesses, it is essential to carry out a
multiplicity of different analyses and assess their poten-
tially conflicting results in the context of broad knowl-
edge about clinical processes and patient behaviors. This
virtually guarantees that reports of research results from
non-intervention studies will be more lengthy and com-
plex than their clinical trial counterparts.
Sample size considerations
Unlike an RCT, at this stage of EMR-based research
we do not have simple, prespecified hypotheses to test.
Furthermore, in the light of the desirability of carrying
out multiple types of analyses with different endpoints
and analysis variants, it is not feasible to make stan-
dard sample size computations. Instead, study justifica-
tion rests on the very large pool of eligible patients
(122, 896 health plan members with EMR-identified
CMP from 2006 to 2010) and analysis relies on precise
estimation of potential effects, rather than on statistical
decision-making. Moreover, part of the purpose of an
EMR-based study is to portray the variability of
response patterns at the individual patient level (as
opposed to an average result for the entire sample) to
the extent that this is observable. Here again, statistical
decision-making does not seem to be an optimal
approach.
Survey of A/C use by CMP patients
Our first-step Phase 1 analyses are confined to vari-
ables available in the EMR, which we will use to
develop a broadly replicable and efficient approach to
evaluating A/C impact. However, patients may be
using A/C and other CAM therapies in ways not visi-
ble within the EMR. Similarly, there may be patient
characteristics contributing to the decision to use A/C
therapies that are also not readily visible in the EMR.
To address these issues, we will identify patients whose
EMR records suggest the presence of CMP within the
past two years; we will then invite them to complete a
survey identifying current and prior out-of-plan A/C
use and use of related treatments/practices. A copy of
t h es u r v e yi sa v a i l a b l ef r o mt h ef i r s ta u t h o r .W ew i l l
then replicate the Phase 1 procedures (described
above) with the enhanced data set including only those
individuals who responded to the survey. This will
allow us to evaluate the robustness of our findings by
comparing the MCG characteristics identified using
only EMR data with those identified in this augmented
data set. Additional insights and characteristics predic-
tive of out-of-plan use will help guide sampling of
CMP participants for the focus groups in Phase 2, as
well as the MCG design for matching participants in
Phase 3. Data on out-of-plan use will be most accurate
for current use patterns, which are most important for
Phases 2 and 3. There will still be “noise” in this data
for two reasons: first, not all CMP patients will
respond to the survey; second, retrospective self-
reporting may not allow us to determine with certainty
whether self-care practices or out-of-plan CAM use
preceded receipt of covered A/C care. Nonetheless,
reporting such practices indicates a patient’s general
proclivity to seek CAM services or engage in self-care
practices to address health concerns. Information on
this tendency may enhance our interpretation of
patient decision-making and outcomes.
Table 4 Phase 1: EMR-derived Clinical Outcomes
Overall use of health care services
Medication use (opiates, sedatives, hypnotics, and antidepressants)
Pain-related procedures (injections, imaging, surgery)
Pain-related visits (primary and specialty care)
Emergency room/Urgent care visits
Evidence of sleep problems
Adverse events attributed to conventional, acupuncture, or chiropractic
care treatment for chronic musculoskeletal pain
Mood disorder diagnoses (depression, anxiety)
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Using Qualitative Methods
T h es e c o n dp h a s eo ft h ep r o j e c tw i l lu s eq u a l i t a t i v e
research methods to achieve three goals: first, to identify
characteristics of A/C received by CMP patients through
A/C provider interviews; second, to explore patients’
and allopathic providers’ decision-making processes in
choosing to use/recommend A/C; and third, to identify
important outcomes and factors associated with patient
and provider satisfaction. Each of these components will
inform the construction of instruments for Phase 3.
Study procedures
For this study phase, we will use qualitative methods
because they can elicit the participants’ perspectives in
defining the range and variability of beliefs, behaviors,
and experiences, all within the context of the natural
language people use to discuss these issues. Qualitative
methods will also allow us to discover themes not
anticipated by study investigators. Standardized
approaches [68-70] will guide research activities. Our
data collection methods will include focus group inter-
views [71-74] and in-depth interviews [68,75,76], ana-
lyzed using a content analysis approach [68].
Through a descriptive case-study approach, we will
investigate the full range of details of A/C use, including
processes by which allopathic providers decide to make
A/C referrals, how CMP patients decide to use such ser-
vices, and how A/C providers decide the components of
care to deliver. The primary questions that guide this
case-study research are: (1) What are the barriers and
facilitators to seeking/referring A/C for CMP patients?
(2) What are the nature and extent of the services
received from acupuncturists and chiropractors (i.e., ser-
vices broader than needling for acupuncture and spinal
manipulation for chiropractic care)? and (3) What are
the clinical, functional, and quality-of-life outcomes
patients and providers associate with receipt of A/C,
and which processes or outcomes are most closely asso-
ciated with patient and/or provider satisfaction?
Phase 2 qualitative data will be collected in two waves:
we will use information from the first wave to refine the
questions asked during the second wave interviews and
focus groups and, ultimately, to collect data on potential
confounders (i.e., patient factors related to decisions to
use A/C services not reflected in EMR data) for use in
Phase 4 analyses.
Focus groups with patient participants
T h ef o l l o w i n gt y p e so fp a t i e n t sw i l lb er e p r e s e n t e d
among those we interview: (1) patients who were clini-
cian-referred and received A/C services; (2) patients
who received A/C without a clinician referral; and (3)
comparable CMP patients who have not received A/C
(including those referred who did not follow through).
We will use data collected through Phase 1 EMR ana-
lyses and out-of-plan surveys to identify these types of
patients for sampling. We anticipate holding multiple
focus groups for each category of participants. Those
who received acupuncture and chiropractic care will be
recruited for separate focus groups.
Focus groups are an efficient mechanism for investi-
gating how people conceptualize, experience, and talk
about issues, for examining a range or consensus of
experiences, and for collecting qualitative data from
many individuals in a short time. Focus groups will be
audio-recorded and consist of 6-12 participants, an opti-
mal size range for discussing behaviors and experiences
[73]. Each patient focus group will address the three
main topics described above. As part of that process, we
will explore two additional issues related to the deci-
sion-making process as shown in the model in Figure 1:
factors that prompt individuals to seek and, once
initiated, continue or discontinue A/C care, and reasons
for deciding to seek care with or without primary care
provider concurrence. The first wave focus group results
will be used to refine the draft Phase 3 questionnaires.
Second wave focus groups of prior A/C users will be
asked to complete the draft questionnaires prior to
focus group attendance and be prepared to advise
researchers on domains or questions relevant to their
use of A/C services not covered in the questionnaire, as
well as to comment on their understanding of the ques-
tions we designed. We will not alter questions that are
part of validated instruments, but we will use the feed-
back to refine our overall assessment battery and to
adjust items that we have created based on first-wave
focus groups.
Health care provider participants
In in-depth interviews, researchers will introduce a ser-
ies of prepared, open-ended questions designed to elicit
factual information on treatment (A/C providers) and
referral (allopathic providers) practices, as well as provi-
ders’ knowledge, beliefs, attitudes, and experiences relat-
ing to A/C for CMP conditions, including what they
would perceive to be clinically meaningful improvement.
An interview guide, ongoing QA meetings, and tran-
script reviews will assure uniformity of approach and
coverage in the interviews. We will conduct in-depth
interviews with acupuncturists and chiropractors who
see a high volume of CMP patients from the health plan
to learn about their treatment styles and decision-mak-
i n gp r o c e s s e sf o rC M Pp a t i e n t sa sw e l la st h e i re x p e r i -
ences with KPNW members who are physician-referred
or self-referred. We will also interview health plan pro-
viders, sampling from among those with high numbers
of A/C referrals, those with some A/C referral history,
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patients for acupuncture or chiropractic services.
Qualitative data analysis
Audio recordings of all focus groups and interviews will
be transcribed verbatim using standardized transcription
protocols. Using content analysis techniques, we will ana-
lyze transcripts and field notes [68,77,78] in two stages.
First, we will use topical indexing to identify text pertain-
ing to each interview question and prompt, followed by
development of a more detailed coding scheme to cap-
ture content, themes, and sentiments. Data management
and reduction will be supported by use of ATLAS text
analysis software (Sage-Scolari, Thousand Oaks, CA). We
will compare participant responses within and across
categories to identify beliefs, attitudes, behaviors, and
experiences important to understanding decisions to seek
and continue A/C care and outcomes associated with A/
C care for CMP. We will analyze response frequency and
content and the vocabulary describing concepts and
experiences. This will allow identification of key issues by
exploring areas of consensus and contradiction within
and across focus group participants and provider respon-
dents [68,79]. Potential bias will be minimized and data
credibility enhanced through comprehensive training of
interviewers and coders, and multiple members of the
research team will complete each type of task. Coder
reliability will be determined through check-coding of 1
out of every 6 interviews and focus groups. Because
ATLAS can interface with statistical programs, partici-
pant characteristics and responses to quantitative ques-
tions (e.g., questionnaire draft) can be included in the
database and will enable us to retrieve text specific to
respondent subgroups.
Phase 3: Prospective Cohort Study to Evaluate Outcomes
Associated with the Use of A/C Services
To conduct a prospective cohort study of carefully
matched A/C and non-A/C patients, we will use cluster-
ing and matching methods identified in Phase 1. These
matching approaches will be refined by Phase 2 qualita-
tive findings and augmented by additional, directly
assessed, patient-reported baseline data. We will follow
matched patients to examine outcomes, which will
include EMR (service utilization and health care costs)
and patient-reported clinical, psychosocial, and QOL
outcomes over a one-year prospective timeframe for
each patient. We will compare outcomes from the pro-
spective cohort to those found during Phase 1 EMR-
only analyses. Specifically, we will conduct the following
activities:
1. Set up a weekly surveillance tracking system to
identify CMP patients referred for A/C care to allow
timely recruitment of these (index) patients and two
carefully matched CMP control patients.
2. Coordinate telephone or online assessments for
index and comparison patients upon recruitment (base-
line; prior to A/C care) and at 1-, 3-, 6-, and 12-month
follow-ups.
3. Compare outcomes (clinical and psychosocial/QOL/
satisfaction outcomes and health care utilization) and
explore health care costs between those receiving A/C
and comparison patients not receiving such services,
examining relationships between patient characteristics
and decisions to use A/C.
4. Conduct comparative and sensitivity analyses
between results using methods that rely solely on EMR-
derived data (Phase 1) with those supplemented by
patient and provider data (Phase 3).
Phase 3 participants and recruitment
Index participants (i.e., those with an incident A/C
referral, n = 200 acupuncture and 200 chiropractic) and
matched comparison participants in this prospective
portion of the study must meet the overall CMP eligibil-
ity criteria listed in Table 1 and be able to read and
respond to assessment questionnaires. Both index and
comparison patients must have had no A/C treatment
over the previous six months to ensure that we are pro-
spectively following a new episode of A/C care. We pur-
posefully minimized exclusion criteria to ensure that
study findings are as broadly representative of the CMP
population as possible.
Health plan members will be recruited over a two-year
period through a weekly EMR review to identify CMP
patients referred for A/C. Those referred for A/C will
be mailed an invitation to the study, including a bro-
chure and letter describing the study, and indicating
that a staff member will call soon to tell them more
about the study. There will also be a study website
where prospective participants can log on to learn more
about the study and eligibility or opt out if they so
choose. Eligible participants will be guided through the
consent process and baseline assessments by an inter-
viewer or online, according to their preferences.
Identification of comparison participants
To recruit comparison cases for each participant in our
cohort of A/C users, we will identify CMP-patient
matches using the clustering/matching approach deter-
mined from Phase 1 and refined based on Phase 2 find-
ings. As with Phase 1, participants must have a primary
care visit within one month of the index patients’ A/C
referral so that we know that an opportunity for A/C
referral existed. When an index patient enrolls online,
the matching process is triggered: those matches will be
located, mailed the same informational materials, and
invited to enroll online. We will recruit two or more
comparison participants for every index participant. A
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fer of comparison participants in the event that some
report A/C use during the assessment window.
Outcome measures and study instruments
The assessment schedule for standardized question-
naires and delineation of EMR-collected outcomes are
shown in Table 5. Patient-reported outcomes are mea-
sured in a time frame (1-12 months) consistent with
many RCTs and other outcome studies of A/C
[19,80,81]. Assessment instruments and domains are
consistent with the Initiative on Methods, Measurement,
and Pain Assessment in Clinical Trials (IMMPACT)
recommendations [82,83]. In addition, we include vari-
ables representing patient factors influencing the
decision to use CAM [43] (Figure 1 plus others identi-
fied in Phase 2) to help refine matches of those who do
and do not seek A/C.
Primary outcomes: Pain and related disability
Two subscales–the 4-item pain severity and the 7-item
pain interference subscales–from the short form of the
Brief Pain Inventory (BPI-SF)[84,85] will be used to
assess pain and related disability. The BPI has sound
psychometrics and has been widely adopted for clinical
pain assessment, epidemiological studies, and studies of
treatment efficacy. We will also include a measure of
how bothered participants are by their pain. This instru-
ment uses a 0 to 10 scale of “symptom bothersomeness,
“ where 0 represents “not at all bothersome” and 10 is
“extremely bothersome.” This question has been
Table 5 Phase 3 Assessment Schedule
Assessment Month
0 1 361 2
Chronic Musculoskeletal Pain Patient Measures:
Pain and related disability (patient-reported, primary outcomes)
Pain Severity (BPI-SF subscale) √ √ √√√
Pain Interference (BPI-SF subscale) √ √ √√√
Pain Bothersomeness (single item) √ √ √√√
Secondary Outcomes (survey instruments)
Overall well-being (Arizona Integrative Outcomes Scale) √ √ √√√
Patient global impression of change √ √√√
Quality of sleep (ISI) √ √ √√√
Work- and activity-related impairment (NHIS questions) √ √ √√√
Depression (PHQ-8)
1 √ √ √√√
Anxiety (GAD-2)
1 √ √ √√√
Quality of Life/health utility index (SF-12) √ √ √√√
Patient satisfaction √√
Secondary outcomes (health care utilization collected through EMR and administrative records)
Overall use of healthcare services and associated costs EMR
2 EMR EMR EMR
Use of medications (short and long-acting opiates, sedatives, hypnotics, antidepressants) EMR EMR EMR EMR
Pain-related procedures (injections and imaging) EMR EMR EMR EMR
Pain-related visits (primary and specialty care) EMR EMR EMR EMR
ER/urgent care visits EMR EMR EMR EMR
Adverse events associated with conventional and CAM CMP treatment
3 EMR EMR EMR EMR
Use of health insurance reimbursed CAM A
4 AAA
Patient characteristics and potential moderators (including predisposing, enabling, and need factors associated with A/C use decision
from Figure 1)
Demographics √
Received/seeking pain-related disability compensation √
Patient expectations/CAM attitudes √
Other characteristics of pain condition (type(s)/duration) √
Previous use of acupuncture/chiropractic services (adapted from NHIS survey) √
Utilization of non-plan CAM health services & products √ √√√
Healthcare Provider (Allopaths/Acupuncturists/Chiropractors) Measures:
Allopathic provider characteristics and CAM beliefs √
Acupuncturist/chiropractic service provided & general practices √√
Note:
1depression and anxiety about pain will also be examined as potential moderators of pain outcomes;
2EMR = electronic medical record,
3participants will
also be asked directly about CMP treatment-related adverse events;
4A = administrative record;
DeBar et al. BMC Complementary and Alternative Medicine 2011, 11:118
http://www.biomedcentral.com/1472-6882/11/118
Page 11 of 18frequently used in studies of back pain [18,19,86] and
shown to have adequate construct validity [87].
Secondary outcomes (patient-reported)
a. Global assessment of change. The Patient Global
Impression of Change scale (PGIC [88]) will be used to
evaluate participants’ overall evaluation of the impact of
their A/C treatment.
b. Work-related impairment. Three questions about
work/disability status and missed work due to CMP will
be adapted from the National Health Information Sur-
vey (NHIS) [89].
c. Depression severity. Using the Personal Health
Questionnaire (PHQ-8) [90,91], we will measure depres-
sion severity. The PHQ-8 is established as a valid
screener and severity measure for depressive disorders
in large clinical studies [90,92-94]. Baseline depression
will also be examined as a possible moderator of
outcome.
d. Anxiety. The 2-item Generalized Anxiety Disorder
Scale (GAD-2) [95,96] will be used to screen for anxiety
disorders. The GAD-2 has been used to detect anxiety
disorders in primary care and has well established psy-
chometric properties. Baseline GAD-2 scores will also
be examined as another possible moderator of outcome.
e. Quality of life/health utility. The SF Health Survey
(SF-12v2) [97] will be used to measure quality of life.
The SF12 is a widely used and well-validated generic
measure of functioning that is a recommended
IMMPACT measure for examining functioning (this will
also be used as a health utility measure) [82].
f. Patient satisfaction. Finally, participant satisfaction
with services provided by the health plan (allopathic
providers) (0 = worst health care possible, 10 = best
health care possible) will be assessed as well as satisfac-
tion with A/C provider when pertinent [98]. We will
also use the practitioner skill subscale from a self-report
outcome measure designed for assessing CAM treat-
ments [99,100].
Secondary outcomes (health care utilization through EMR
and administrative records)
These EMR-based outcome measures were listed in
Table 4 as they also form the basis for our Phase 1 out-
come analyses.
Patient characteristics and potential moderators
include factors that may influence decisions to use
CAM (see Figure 1)[101] or that have been found to
moderate pain-related outcomes [102-104]. These fac-
tors might then be used as additional baseline matching
variables or covariates to maximize comparability
between index- and matched comparison-participants
included in the analyses. Demographics include age,
gender, race/ethnicity, education, marital status, employ-
ment status, income, and income source. Administrative
records will identify participants seeking or receiving
worker’s compensation or other disability payments for
their CMP. This will be augmented by a single-item
question about disability status of participants on the
questionnaire. We will assess general preventive beha-
vior [105,106] by collecting data on self-management
behaviors including physical activity practices. In addi-
tion, we will assess participants’ general expectations of
CMP improvement, improvements with A/C treatment
[27,31], and how helpful a variety of CAM services and
practices (provider- and self-directed) may be [107]. We
will measure other characteristics of the participant’s
pain condition, including age of onset, perceived etiol-
ogy of CMP, and type(s) of current CMP. Finally, we
will collect data on use of other CAM services/products,
including any CAM treatment visits not referred
through the health plan (e.g., chiropractic and acupunc-
ture, massage therapists, naturopaths) as well as CAM-
related self-care practices (e.g., yoga, meditation, tai chi)
and products (e.g., dietary supplements).
Health care provider measures
a. Allopathic provider characteristics and factors asso-
ciated with A/C referrals including questions describing
general provider characteristics (i.e., gender, specialty
type, professional degree, years in practice, and training/
expertise in CMP) and A/C referral attitudes, as well as
an EMR-based variable reflecting the inclination for a
given provider to refer for A/C services (referral rate per
CMP patients on panel).
b. A/C provider characteristics and treatment patterns
include questions adapted from the A/C-visit data forms
developed by Sherman and colleagues [108] and refined
during our Phase 2 interviews with the CAM providers.
We also have access to data collected by the health plan
on CAM-referred services patients receive (e.g., number
of sessions; assigned diagnostic, procedure, and treat-
ment [CPT] codes.
Phase 3 Data Analysis
Patient-reported outcomes
For the patient-reported outcomes in Phase 3, we will
examine differences in baseline measures between parti-
cipants with and without data at the 1-, 3-, 6-, and 12-
month follow-ups. Variables related to missingness will
be included in the main analyses as covariates to reduce
bias in the estimates [109,110].
We will use multilevel modeling to examine differ-
ences across time in primary (pain intensity/interfer-
ence/bothersomeness) and secondary patient-reported
outcomes between A/C users and matched comparison
participants. Two parameters (linear and quadratic
slope) will characterize change across time, with linear
slope capturing initial rate of change and quadratic
slope reflecting the degree to which the change slowed
(or increased) over time. Thus, the quadratic model for
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captures nonlinear change across time. Unlike repeated
measures analysis of variance, multilevel modeling does
not require data at all time points from each subject, so
data from all subjects will be included in analyses.
Depending upon the distribution, normal, logistic, or
Poisson models will be used. Importantly, these analyses
can be adjusted using additional information collected
from participants during the baseline assessment that
we may identify in Phase 2 as influencing A/C decision-
making. This will better control for factors not available
during comparison patient identification when only
EMR data will be available for matching/clustering.
EMR-related outcomes
To examine total health care utilization across 12
months, the analysis issues laid out for Phase 1 continue
to apply. Using the MCG as the unit of analysis, the
conventional statistical methods from Phase 1 continu-
ous measures will be assessedb yo n e - s a m p l el o c a t i o n
tests and discrete outcomes will be assessed by binomial
methods or by ordinal multinomial methods in the case
of multiple outcomes. Like Phase 1, MCG characteristics
in the Phase 3 sample will be related to A/C effects
using the models described above. Implementing the
same analytic strategy here as in Phase 1 (i.e., using
EMR data alone), we will be able to test directly for the
contribution provided by the additional prospective
information on patient-and-provider characteristics (e.g.,
pain severity, self-care behaviors, provider attitudes to
A/C referral). We will do so by including patient-sup-
plied variables at the patient level in the analytic model
and then introducing random-effects terms for the
MCGs to account for within-MCG correlation.
Costs
Health plan costs are one of our secondary outcomes, as
we are interested in how total health plan costs differed
between A/C users and nonusers. Costs will be esti-
mated by applying internal unit costs developed and
tested in previous studies [111,112] to the HMO
patient-level utilization measures, with the final cost
variables acting as proxies for HMO resource cost. We
are interested in the effect of patient-level factors–in
particular, patients’ use (or not) of A/C services on
health care costs. Admittedly, the challenges of analyz-
ing typical cost data are well known and significant;
these include 1) having a large proportion of non-users
(i.e., zero costs); 2) the fact that non-zero costs are
usually right-skewed; and 3) heteroscedasticity. Assum-
ing these challenges exist in our study cost data, we will
tackle them by exploring transformation models and
generalized linear models (GLM). Transformation mod-
els convert skewed cost data using a transformation (e.
g., log-normal) to a better-behaved distribution (i.e., one
more normal and symmetric, homoscedastic, less
skewed, promoting more efficient estimation). A compli-
cation of transformations is possible re-transformation
bias in switching from the transformed scale to the ori-
ginal dollar-based scale. GLM avoids re-transformation
bias but can be highly imprecise if the residual pattern
is misspecified. We will explore both model forms to
determine the most accurate and descriptive approach
for our study data. Cost analyses will be performed in
STATA version 11.
Phase 3 Sample Size
We based our Phase 3 sample size determination on the
BPI short form severity (BPI-S) and interference (BPI-I)
subscales. Although these outcome measures are highly
recommended for pain studies [82], it is difficult to find
the appropriate statistics reported in the literature, that
are required for design purposes. We have relied on the
findings from the SCAMP intervention [113,114] and
Tan’s and colleagues’ validation study of the use of the
BPI for chronic nonmalignant pain [115], who reported
SD = 2 (approximately) for both the severity and inter-
ference subscales of the BPI in large samples of patients
with nonmalignant pain. Changes on the order of 1-3
points have been cited as being relatively common [116]
and within the range of change found in the SCAMP
intervention [113,114]. Collectively, these sources sug-
gest that an attainable and clinically meaningful effect
size would be 0.50, which translates into a difference
between mean changes of 1 unit (absolute). For 100
patients in each of two groups, assuming a 0.5 correla-
tion between pre- and post-measurements, using a con-
ventional two-sample t-test with a two-sided
significance level of 0.025 (to allow for two tests), the
power would be slightly over 90% to detect a 1 unit
treatment effect. The analysis we intend to use would be
more efficient, because it would adjust for baseline BPI
values, but we might also want to include explanatory
factors into the analysis, which might decrease effi-
ciency. Consequently, we propose group sizes of 200, for
a total of 1, 200 - that is a total of 200 participants each
for those receiving acupuncture and chiropractic ser-
v i c e sa sw e l la st w om a t c h e dc o m p a r i s o nC M Pp a r t i c i -
pants for each of these index participants for a total
sample size of 1, 200. Table 6 shows sample and effect
sizes for a number of recent studies of related pain con-
ditions utilizing related meas u r e sa sw e l la sa n t i c i p a t e d
effect size estimates for thec u r r e n ts t u d y .W h i l et h e s e
comparative clinical trials may have possibly produced
greater effect sizes than we will observe in this observa-
tional study, our proposed group size is substantially lar-
ger than those reported for each of these studies.
To estimate available numbers of CMP patients who
may receive A/C care for the Phase 3 prospective cohort
study, we examined the number of health plan referrals
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patterns for A/C among health plan members with
CMP (see Figure 3) are fairly stable, with an average of
330 acupuncture and 303 chiropractic referrals monthly;
therefore, we should have an adequate recruitment pool
(estimate of 15, 192 A/C referrals with CMP over the
two-year recruitment period) to meet the target enroll-
ment for this phase of the study.
Ethical Approval
Written consent will be obtained from each participant
in Phases 2 and 3 and from those completing the out-
of-plan A/C survey in Phase 1. For the data-only portion
of Phase 1, health plan members’ contracts with the
HMO provide consent for use of their data in HMO-
sponsored research studies. This study protocol was
approved by the institutional review boards (IRB) of Kai-
ser Permanente Northwest, University of Arizona, and
Oregon Health and Science University. This study pro-
tocol is registered with http://www.clinicaltrials.gov
(NCT01345409).
Discussion
We expect that successful completion of this study will
provide an evaluation of the outcomes–from the per-
spectives of patients, providers, and health services utili-
zation–associated with the real-world use of A/C
services. By comparing the results of the EMR-only ana-
lyses with the more comprehensive results available in
Phase 3, we will be able to identify the strengths and
weaknesses of EMR-alone analyses and potentially iden-
tify the most critical additional data needed. We further
anticipate that the trio of EMR-based analyses, qualita-
tive assessment, and prospective cohort studies will pro-
vide a clearer understanding of the decision-making
processes behind the use of A/C for CMP; these will
also provide a transportable methodology that can be
applied to other health care settings, CAM treatments,
and clinical populations.
With regard to advancing our understanding of
patients’ use of CAM in everyday practice settings,
much CAM research to date has focused narrowly on
“early adopters” (those likely to use CAM services
regardless of barriers [117]). Yet within our cohort, cost
and access barriers are substantially reduced, allowing
us to study other factors (see Figure 1) influencing A/C
care receipt and outcomes and to develop a comprehen-
sive characterization of A/C use patterns and outcomes
in patients with increasing access to such CAM services.
An important goal of this study is to clarify how CMP
patients use A/C compared to conventional care (to
augment or replace it), when and why patients disclose
A/C use to allopathic providers, and how such practices
may vary by patient characteristics. Our mixed methods
approach will help us develop a better understanding of
the process behind the decision to initiate (patients),
recommend (allopathic providers), and continue
(patients and providers) A/C care for the treatment of
CMP. Finally, studying this in everyday treatment set-
tings allows us to consider the range of services received
in A/C care (e.g., needling or spinal manipulation vs.
Table 6 Sample and Effect Sizes for Related and Current Study
Study Condition Treatment Assessment Scale Group size Effect size
Cherkin, 2009 [19] chronic LBP acu RMDQ 160 0.46
Cherkin, 2009 [19] chronic LBP acu bothersomeness 160 0.42
Liang, 2011 [118] chronic neck pain acu NPQ 81 0.24
Franca, 2008 [119] tension headache acu v PT VAS pain 16 2.0
Molsberger, 2010 [120] shoulder pain acu v UC VAS pain 150 1.01
Hondras, 2009 [121] LBP > 55 yrs chiro v UC RMDQ 90 0.3
Kroenke, 2009
(as reported in Krebs, 2010)[113,114]
musculoskeletal pain Rx/self care v UC BPI-S, BPI-I 125 0.56 (BPI-S) 0.59 (BPI-I)
Current study musculoskeletal pain acu v UC BPI-S & BPI-I 200 0.5*
Current study musculoskeletal pain chiro v UC BPI-S & BPI-I 200 0.5*
Note: LBP - lower back pain; acu - acupuncture; chiro - chiropractic care; LM - light massage; RMDQ - Roland Morris Disability Questionnaire; NPQ - Northwick
Park Neck Pain Questionnaire; BPI-S - Brief Pain Inventory Severity Subscale; BPI-I - Brief Pain Inventory Interference Subscale; * estimated ES
Figure 3 Health Plan Patients with Chronic Musculoskeletal
Pain (CMP) Receiving New* Acupuncture and or Chiropractic
Care (A/C) Referral.
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tics of the CMP patient and/or A/C provider.
In addition to advancing our understanding of real
world A/C practices and their impact on CMP, this
study affords us the opportunity to build upon the
increasingly available EMR systems to conduct research
that may be more broadly adopted to better understand
the real world interplay of conventional medicine and
A/C services. Using EMRs exclusively may limit infor-
mation on important variables (covariates) on which to
match or cluster like patients. However, by augmenting
data sets through direct reports by providers and
patients regarding important decision-making factors
suggested by qualitative findings, we may substantially
reduce potential confounding in comparing those who
do and do not receive A/C treatment. Thus, we can
identify whether widely available data in EMR and
administrative systems can be used to adequately fore-
cast patients’ outcomes and evaluate the extent to which
supplementation from additional patient- and provider-
collected information is a necessary adjunct to EMR-
based data analysis.
Finally, our MCG-focused methodology gives us a
unique opportunity to conduct patient-centered
research; that is, to identify like groups based upon
actual individual patient care characteristics rather than
hypothetical group averages. A typical RCT may not
include enough participants to form homogeneous clus-
ters for separate evaluation, yet an EMR database of a
large clinical population like the CMP sample described
here does include sufficient numbers of patients with
similar characteristics and disease severity to form clini-
cally meaningful clusters as the basis of the analyses.
Accordingly, this research may allow us to address the
clinical question as follows: for whom does supplemen-
tary CAM care result in clinically significant improve-
ments in pain severity and overall functioning? Our
planned MCG methodology will allow us to identify the
characteristics of CMP patients for whom A/C may
have the greatest impact on satisfaction, functioning,
clinical, and QOL outcomes; it will also clarify whether
the timing of services relative to conventional care and
the course of the CMP affects such outcomes.
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